Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...
A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...
Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...